--- title: "What Does Research Use Only (RUO) Mean? FDA Rules" description: "Research use only is a lab label, not a legal route to patients. Why FDA treats RUO peptides sold for human use as drugs, and what Cuvo Health runs instead." canonical: "https://cuvo.co/glossary/research-use-only" last-updated: "Oct 26, 2026" --- **Definition:** Research use only (RUO) is a label saying a product is for laboratory research, not use in people; federal rules define it for in vitro diagnostics in 21 CFR 809.10(c). For drugs it is no legal shield: FDA judges a product by intended use, so an RUO product sold for human use is a drug. # What are research use only (RUO) products? Online sellers label peptide vials "research use only" while marketing them in ways that point to human use. FDA does not accept the label when the circumstances show the product is meant for people. Cuvo Health runs the lawful alternative: a provider-prescribed program filled by licensed pharmacies. Published Oct 26, 2026. Facts reviewed Oct 26, 2026. Research use only (RUO) is a label stating that a product is meant for laboratory research and not for use in people. Federal rules define it for in vitro diagnostic products, whose research-phase labeling must read "For Research Use Only. Not for use in diagnostic procedures." (21 CFR 809.10(c)(2)(i)). There is no comparable route for a drug sold to the public. FDA decides what a product is by its intended use, shown by labeling, advertising, statements and the circumstances of sale (21 CFR 201.128), so an RUO-labeled product sold for human use is regulated as a drug. On Cuvo Health, the peptide program is limited to compoundable, provider-prescribed options, and no research-use-only product is sold or routed. **At a glance** - Where it is defined: In vitro diagnostic labeling, 21 CFR 809.10(c)(2)(i) - Investigational drugs: Carry a different caution statement under 21 CFR 312.6 - The test FDA applies: Intended use, under 21 CFR 201.128 - Enforcement: August 24, 2026 warning letter: research-labeled products for human use were unapproved new drugs - The lawful route: A licensed provider's prescription, filled by a licensed pharmacy - On Cuvo: Peptides limited to compoundable, provider-prescribed options; no RUO products **Labels that sound alike, and what each allows** | Label or route | What it is | Lawful route to a patient | | --- | --- | --- | | **"For Research Use Only" (diagnostics)** | A research-phase in vitro diagnostic, 21 CFR 809.10(c)(2)(i) | None; not for diagnostic procedures | | **Investigational new drug caution** | A drug under clinical investigation, 21 CFR 312.6 | Only inside the investigation | | **"Research use only" on a drug sold online** | A marketing label with no drug status | None; FDA treats it by intended use | | **Compounded prescription** | A preparation for an identified patient under 503A or 503B | Yes, when every condition is met | ## 01. Why does research use only matter for a telehealth brand? Because a brand that resells such vials, or points its customers to a seller, puts its own name next to products FDA treats as unapproved drugs. In a warning letter dated August 24, 2026, FDA found that despite "research use only" and "not for human or animal consumption" statements, the seller's own website established the products were intended as drugs for human use. FDA cited bacteriostatic water sold alongside a peptide guide and calculator, and the products named included research-labeled semaglutide and tirzepatide. ## 02. Is a research use only label a legal defense? No. Under 21 CFR 201.128, intended use is the objective intent of the seller, shown by claims, advertising, statements and the circumstances in which the product is offered. In the August 2026 letter FDA classed the research-labeled products as unapproved new drugs and cited sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act. A disclaimer cannot change what the rest of the page shows. ## 03. How is an RUO product different from a compounded prescription? A lawful compounded preparation under section 503A starts with a valid prescription for an identified patient, uses bulk ingredients that meet one of three statutory tests from an FDA-registered maker with a certificate of analysis, and is dispensed by a licensed pharmacy. An RUO vial has none of that. On Cuvo, a provider licensed in the patient's state decides whether any treatment is appropriate, and each prescription routes only to a licensed pharmacy operating inside current rules. This is general information, not legal advice. ## Frequently asked questions **Q: What does research use only mean?** A: It is a label saying a product is for laboratory research and not for use in people; federal rules define it for in vitro diagnostics. On Cuvo, no research-use-only product is sold or routed to patients. **Q: Are research use only peptides legal?** A: Selling them for human use is not: FDA judges a product by its intended use, and in an August 24, 2026 warning letter it treated research-labeled products sold for people as unapproved new drugs. On Cuvo, the peptide program is limited to compoundable, provider-prescribed options. **Q: Can a brand sell research use only peptides?** A: Not to consumers for human use, and a disclaimer does not change that, because the seller's marketing and the circumstances of sale show the intended use. Cuvo Health gives a brand the lawful version: a provider-prescribed program filled by licensed pharmacies under the brand's name. **Q: RUO vs compounded peptides: what is the difference?** A: A compounded peptide is prepared by a licensed pharmacy on a prescription for an identified patient under section 503A or 503B, while an RUO vial has no prescription, no patient and no drug status. On Cuvo, every peptide prescription comes from a licensed provider and routes to a licensed pharmacy operating inside current rules. **Q: Does Cuvo offer research use only products?** A: No. Cuvo Health's peptide program is limited to compoundable, provider-prescribed options, decided by a provider licensed in the patient's state and filled by a licensed pharmacy. **Related pages** - [FDA peptide compounding rules in 2026](/blog/fda-peptide-compounding-rules-2026): The 2026 enforcement and policy timeline - [Peptide programs on Cuvo](/solutions/peptides): Provider review and licensed pharmacy routing - [FDA bulk drug substance categories](/glossary/bulk-drug-substance-categories): Which ingredients may be compounded - [Compounded medication](/glossary/compounded-medication): The lawful, prescription-based route - [How to start a peptide business](/blog/how-to-start-online-peptide-business): The launch sequence for a prescription peptide brand Canonical page: https://cuvo.co/glossary/research-use-only